The invention provides methods of using low coverage sequencing to assess the relative fraction of tumor versus normal DNA in a sample, and to assess copy number alterations present in the sample.

Provided herein are methods of identifying the spatial location of a nucleic acid in a biological sample. In some embodiments, the methods employ a template switching oligonucleotide. In some embodiments, the methods extend the capture probe to create a complementary DNA (cDNA) molecule of a capture analyte and produce second strand in one reaction.

Disclosed are nucleic acid oligomers, including amplification oligomers and detection probes, for amplification and/or detection of human coronavirus OC43,HKU1, NL63, and/or 229E nucleic acid. Also disclosed are methods of nucleic acid amplification and/or detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

An in vitro or ex vivo method for determining the risk of occurrence of a healthcare-associated infection in a patient, including a step of measuring the expression of CX3CR1, in a biological sample of said patient.

Hybridization probe reagents that specifically detect nucleic acids of C. trachomatis, including wildtype and/or variant sequences identified as FI-nvCT C1515T (SEQ ID NO: 17), JP-nvCT C1522T (SEQ ID NO: 12), US-nvCT G1526A (SEQ ID NO:22), and NO-nvCT G1523A (SEQ ID NO:27). Certain probes include nucleotide analogs to enhance desirable binding properties.

Systems and methods for rapid diagnostics related to the use of CRISPR effector systems and optimized guide sequences, including multiplex lateral flow diagnostic devices and methods of use, including for detection of cancer markers, are provided.

Disclosed herein are methods for a RNA in situ hybridization assay workflow for the detection of target RNA within intact cells for the detection of prostate cancer cells in urine samples. The methods disclosed herein can identify a genetic susceptibility to prostate cancer in a subject and differentiate high risk from low risk prostate cancers. The methods disclosed herein can also include treatment and management strategies for prostate cancer and the prevention thereof.

The present disclosure relates to primer and probe sets for pathogen detection of infection in a transplant patient, a kit and use thereof, and belongs to the technical field of molecular biology detection. There are 23 primer and probe sets that can be used to jointly detect 23 kinds of pathogens with a high infection rate and a high lethality rate after transplantation, including an adenovirus type B; and two ends of a corresponding sequence of each probe have correspondingly a fluorophore and a quencher group, respectively. The present disclosure further provides a real-time fluorescence quantitative PCR kit for pathogen detection of infection in a transplant patient, including the primer and probe sets, a pathogen plasmid standard, a fluorescence quantitative PCR reaction solution, and sterile deionized water, which can simultaneously detect 23 pathogens infected by the transplant patient.

The present invention discloses markers, primers, probes and a kit for early screening and diagnosis of endometrial cancer. The markers are partial methylated regions in the four genes of CDO1, CELF4, HAND2 and HS3ST2. Detection primers and probes are designed for these methylated regions and to have clasp structures. The kit includes the aforementioned primers and probes. The present invention screens and combines multiple methylated regions to determine the most suitable methylated position for combined diagnosis, which can significantly improve the sensitivity and specificity of the detection for early endometrial cancer. The kit is especially suitable for early screening and diagnosis of endometrial cancer with cervical exfoliated cells as a sample. Even if the DNA template concentration is low, endometrial cancer can be detected. The kit has the advantages of non-invasive sampling, fast detection speed, higher sensitivity and specificity, etc., and can ensure the accuracy of the results to help achieve the purpose of early detection, early diagnosis, and early treatment of endometrial cancer.

Disclosed are oligonucleotide primers that hybridize specifically with any base sequence designed from the base sequences of the N gene, RNA-dependent RNA polymerase gene, M gene, and S gene of SARS-CoV-2, a nucleic acid amplification method using said primers, a test method for SARS-CoV-2 infection by detection of nucleic acid amplification, and a COVID-19 test kit.